These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29707830)

  • 1. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?
    Moradi H; Streja E; Vaziri ND
    Semin Dial; 2018 Jul; 31(4):398-405. PubMed ID: 29707830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in patients with chronic kidney disease.
    Hager MR; Narla AD; Tannock LR
    Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are HMG-CoA reductase inhibitors underutilized in dialysis patients?
    Seliger SL; Stehman-Breen CO
    Semin Dial; 2003; 16(3):179-85. PubMed ID: 12753674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins in the management of dyslipidemia associated with chronic kidney disease.
    Epstein M; Vaziri ND
    Nat Rev Nephrol; 2012 Feb; 8(4):214-23. PubMed ID: 22349484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current guidelines for treatment of dyslipidemia in kidney diseases].
    Jędras M; Dylewska M
    Wiad Lek; 2014; 67(3):426-8. PubMed ID: 25782205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid changes and statins in chronic renal insufficiency and dialysis.
    Wanner C; Krane V; Metzger T; Quaschning T
    J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia and the progression of renal disease in chronic renal failure patients.
    Cases A; Coll E
    Kidney Int Suppl; 2005 Dec; (99):S87-93. PubMed ID: 16336584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of end-stage renal disease.
    Schmid H; Schiffl H; Lederer SR
    Expert Opin Pharmacother; 2010 Mar; 11(4):597-613. PubMed ID: 20163271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
    Baber U; Toto RD; de Lemos JA
    Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.